Search

Displaying results 1021 - 1030 of 1804 in total
  1. Target

    Tyrosine-protein phosphatase non-receptor type 2

    go.drugbank.com/bio_entities/BE0012706
    TargetHumans

    Negatively regulates tumor necrosis factor-mediated signaling downstream via MAPK through SRC dephosphorylation. … Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR.

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 2
  2. Target

    Tumor necrosis factor receptor superfamily member EDAR

    go.drugbank.com/bio_entities/BE0021253
    TargetHumans

    Receptor for EDA isoform A1, but not for EDA isoform A2. Mediates the activation of NF-kappa-B and JNK. May promote caspase-independent cell death

    Polypeptides: Tumor necrosis factor receptor superfamily member EDARSynonyms: EDA-A1 receptor, Ectodysplasin-A receptor
  3. Target

    T cell receptor beta variable 6-5

    go.drugbank.com/bio_entities/BE0021562
    TargetHumans

    V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447).

    Polypeptides: T cell receptor beta variable 6-5
  4. Drug

    Taurine

    go.drugbank.com/drugs/DB01956
    ApprovedInvestigationalNutraceutical

    Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. This conditional amino acid can be either be manufactured b...

  5. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval.

  6. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    [L14647] Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as [remifentanil], are designed to be metabolically fragile and thus

  7. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin … Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.

  8. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle … Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA).

    Categories: Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists
  9. Drug

    Alginic acid

    go.drugbank.com/drugs/DB13518
    ApprovedInvestigationalWithdrawn

    Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. … Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (_Phacophycae_) via alkaline extraction.

  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors